Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Gandara, E. Vokes, M. Green, P. Bonomi, R. Devore, R. Comis, D. Carbone, D. Karp, C. Belani (2000)
Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 1
C. Kosmas, N. Tsavaris, M. Vadiaka, N. Stavroyianni, A. Koutras, N. Malamos, A. Onyenadum, S. Rokana, A. Polyzos, H. Kalofonos (2001)
Gemcitabine and docetaxel as second‐line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum‐based regimensCancer, 92
HA Burris, J Eckhardt, S Fields (1993)
Phase II trials of Taxotere in patients with non-small-cell lung cancerProc ASCO, 12
E Rosvold, CJ Langer, R Schilder, M Millenson, E Riemet, K Kreamer (1998)
Salvage therapy with gemcitabine in advanced non-small-cell lung cancer progressing after prior carboplatin-paclitaxelProc. ASCO, 17
S. Kakolyris, E. Papadakis, X. Tsiafaki, C. Kalofonos, A. Rapti, M. Toubis, E. Bania, C. Kouroussis, K. Chainis, N. Androulakis, S. Agelaki, E. Sarra, N. Vardakis, V. Georgoulias (2001)
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.Lung cancer, 32 2
C. Kosmas, N. Tsavaris, H. Kalofonos (2002)
Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent phase II studies.Medical science monitor : international medical journal of experimental and clinical research, 8 6
F. Fossella (1999)
Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials.Seminars in oncology, 26 5 Suppl 16
L. Crinò, A. Mosconi, G. Scagliotti, G. Selvaggi, S. Novello, M. Rinaldi, M. Giulia, C. Gridelli, A. Rossi, C. Calandri, F. Marinis, Mariantonietta Noseda, M. Tonato (1999)
Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 7
C. Spiridonidis, L. Laufman, L. Carman, T. Moore, S. Blair, J. Jones, Christopher George, T. Patel, R. Roach, R. Rupert, J. Zangmeister, D. Colborn, Jens Kuebler (2001)
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.Annals of oncology : official journal of the European Society for Medical Oncology, 12 1
Yuh-Min Chen, R. Perng, W. Lin, H. Wu, C. Tsai, J. Whang‐Peng (2002)
Phase II Study of Docetaxel and Gemcitabine Combination Chemotherapy in Non–Small-Cell Lung Cancer Patients Failing Previous ChemotherapyAmerican Journal of Clinical Oncology, 25
J. Hainsworth, H. Burris, F. Billings, J. Bradof, M. Baker, F. Greco (2001)
Weekly docetaxel with either gemcitabine or vinorelbine as second‐line treatment in patients with advanced nonsmall cell lung carcinomaCancer, 92
F. Fossella, R. Devore, R. Kerr, J. Crawford, R. Natale, F. Dunphy, L. Kalman, V. Miller, J. Lee, M. Moore, D. Gandara, D. Karp, E. Vokes, M. Kris, Y. Kim, F. Gamza, L. Hammershaimb (2000)
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy RegimensJournal of Clinical Oncology, 18
F. Fossella, Jangsoon Lee, D. Shin, Maria Calayag, M. Huber, R. Perez-soler, W. Murphy, S. Lippman, Benner Se, B. Glisson (1995)
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 3
D. Rischin, M. Boyer, J. Smith, M. Millward, M. Michael, J. Bishop, J. Zalcberg, J. Davison, E. Emmett, B. McClure (2000)
A phase I trial of docetaxel and gemcitabine in patients with advanced cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 11 4
G Robinet, JP Kleisbauer, P Thomas (1997)
Phase II study of docetaxel (Taxotere) in first- and second line NSCLCProc ASCO, 16
F. Shepherd, J. Dancey, R. Ramlau, K. Mattson, R. Gralla, M. O'Rourke, N. Levitan, L. Gressot, M. Vincent, R. Burkes, Susan Coughlin, Yong Kim, J. Bérille (2000)
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 10
P Baas, H Codrington, M Muller, O Dalesio, HB Kwa, N Zandwijk (2000)
Second-line gemcitabine therapy in non-small-cell lung cancer stage IIIB and IVProc ASCO, 18
Docetaxel has been the only single active agent against chemotherapy-pretreated non-small-cell lung cancer (NSCLC). The purpose of this phase II study was to evaluate the efficacy and safety of docetaxel combined with gemcitabine, another effective drug, in patients with NSCLC previously treated with platinum-based chemotherapy. Thirty-three patients were enrolled. Prior chemotherapy was cisplatin combined with etoposide in 24 patients and vinorelbine in 9 patients. Tumors were sensitive (n=15), resistant (n=9), and refractory (n=9) to front-line chemotherapy. Treatment was docetaxel 85 mg/m2 on d 1, and gemcitabine 1200 mg/m2 on d 1 and 8, with cycles repeated every three weeks. Ten patients (30.3%, 95% CI: 15.6–48.7) achieved a partial response and 15 (45.5%) stable disease. Responses were similar frequencies in platinum-sensitive and platinum-resistant/refractory tumors. With a median follow-up period of 5.7 mo (range 1.6–20.0), the median and 6-mo event-free survival were 5.5 mo, 40.6%, respectively. Median and 6-mo over-all survival were 7.3 mo and 52.7%. Patients with progressive disease to chemotherapy (p=0.0008), higher LDH (p=0.005), and NSE levels (p=0.03) survived shorter than other patients. In patients refractory to prior chemotherapy, survival was poor as borderline significantly (p=0.06). The major hematological toxicity was neutropenia. Grade III–IV neutropenia was noted in 14 (42%) patients, with three episodes of febrile neutropenia in 111 cycles. Docetaxel combined with gemcitabine is an active and safe second-line therapy for patients with NSCLC.
Medical Oncology – Springer Journals
Published: Jun 2, 2007
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.